NCT01903720View on ClinicalTrials.gov

A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2013

Primary Completion Date

September 24, 2014

Study Completion Date

March 30, 2015

Conditions

Macular EdemaRetinal Vein Occlusion

Interventions

DRUG

dexamethasone implant

OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.

Trial Locations (1)

Unknown

Seoul